Dear Doctor Letter (Rote-Hand-Brief) on Imbruvica® (ibrutinib): risk of hepatitis B re-activation
2017.07.18
Active substance: ibrutinib
The company Janssen-Cilag GmbH is circulating information on the fact that cases of hepatitis B virus (HBV) re-activation have occurred during treatment with Imbruvica®. Therefore, patients should be examined with regard to HBV infection prior to beginning treatment with ibrutinib.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN